New heart pump to begin US trials:
This article was originally published in Clinica
Cardiac Assist Technologies has begun an FDA-approved clinical trial of its heart pump in the US. The five-patient feasibility trial under an Investigational Device Exemption, will be carried out to evaluate the safety of the AB-180 CSS ventricular assist device and to fine-tune the clinical protocol in preparation for multi-centre clinical trials of the device. The Pittsburgh-based company has also begun clinical studies of the device in the UK, Switzerland and South Africa.
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.